KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Current Assets (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Current Assets for 8 consecutive years, with $514.1 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 50.69% to $514.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $514.1 million through Dec 2025, down 50.69% year-over-year, with the annual reading at $514.1 million for FY2025, 50.69% down from the prior year.
  • Current Assets hit $514.1 million in Q4 2025 for Vir Biotechnology, down from $545.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $2.6 billion in Q1 2022 to a low of $514.1 million in Q4 2025.
  • Historically, Current Assets has averaged $1.5 billion across 5 years, with a median of $1.2 billion in 2024.
  • Biggest five-year swings in Current Assets: surged 165.37% in 2022 and later tumbled 50.69% in 2025.
  • Year by year, Current Assets stood at $1.6 billion in 2021, then surged by 61.19% to $2.5 billion in 2022, then tumbled by 36.95% to $1.6 billion in 2023, then crashed by 34.36% to $1.0 billion in 2024, then crashed by 50.69% to $514.1 million in 2025.
  • Business Quant data shows Current Assets for VIR at $514.1 million in Q4 2025, $545.7 million in Q3 2025, and $735.7 million in Q2 2025.